NEUROCRINE BIOSCIENCES INC 4

Leslie V. Norwalk sold 1,250 NBIX common shares for about $227,508 and exercised 842 stock options into shares, ending with 2,140 shares owned.

On July 28, 2026, reporting person Leslie V. Norwalk sold 1,250 shares of Neurocrine Biosciences, Inc. common stock at a weighted average price of approximately $182.006 per share, for proceeds of about $227,508, under a Rule 10b5-1 trading plan. On July 29, 2026, she exercised 842 non-qualified stock options at an exercise price of $139.43 per share, acquiring 842 shares of common stock valued at roughly $117,330 at the exercise price; a corresponding line shows the option exercise (coded “M”) with a price of $0 reflecting the conversion from derivative to common stock, not an additional cash transaction. Following these transactions, her directly held common stock increased to 2,140 shares, with an estimated market value of about $389,482 using the sale price as a proxy. The sales were executed through a broker in multiple trades within a narrow range of $182.00 to $182.03 per share, and the option grant from which the shares were exercised vested in 12 monthly installments beginning June 22, 2024.

Filing Facts

CIK

914475

Ticker

NBIX

Form

4

Source Type

fda

Accession

0001533568-26-000012

Alert Tier

6